Tokyo, Dec. 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060108) titled 'Clinical usefulness of measuring the content of amino acids modified by the Maillard reaction in vivo in acute cerebral infarction' on Dec. 19.
Study Type:
Observational
Primary Sponsor:
Institute - Fukuoka Neurosurgical Hospital
Condition:
Condition - acute ischemic stroke
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The main objectives of this study are to 1 discover the usefulness of this as a new indicator that can predict the progression of acute cerebral infarction, 2 discover the usefulness of non invasive AGE measurement using an AGE sensor in this field, and 3 identify more specific structures that can predict acute cerebral infarction.
Basic objectives2 - Bio-availability
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1. Subjects aged 18 years or older
2. Subjects who are deemed to be thrombectomy recipients by a full-time physician at Fukuoka Neurosurgical Hospital
3. Subjects who have received sufficient information regarding participation in this study and have provided written consent of their own free will
4. Subjects who are unable to make their own decisions, and whose blood relatives have provided written consent
Key exclusion criteria - 1. Those whose thrombus could not be retrieved
2. Those who are otherwise deemed inappropriate by the principal investigator or investigator
Target Size - 200
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 08 Month 15 Day
Date of IRB - 2025 Year 08 Month 12 Day
Anticipated trial start date - 2025 Year 08 Month 15 Day
Last follow-up date - 2029 Year 07 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068465
Disclaimer: Curated by HT Syndication.
